Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1983 • 52,849 citations

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells

1988 • 353 citations

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

1982 • 327 citations

Lymphokine-activated killer cells: A new approach to immunotherapy of cancer

1985 • 314 citations

Biology of tumor progression in human melanocytes.

1987 • 236 citations

Cell-mediated killing: A common mechanism?

1986 • 114 citations

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

1986 • 105 citations

Human tumor xenografts as model for drug testing

1988 • 93 citations

Perforin‐Dependent and ‐Independent Pathways of Cytotoxicity Mediated by Lymphocytes

1988 • 86 citations

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

1986 • 75 citations

Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.

1986 • 72 citations

The pore-forming protein (perforin) of cytolytic T lymphocytes is immunologically related to the components of membrane attack complex of complement through cysteine-rich domains.

1986 • 61 citations

Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin‐2 activated killer cells and by activated monocytes

1987 • 54 citations

Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.

1988 • 47 citations

Perforin — a primary pr auxiliary lytic mechanism?

1988 • 41 citations

Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ

1986 • 40 citations

Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.

1987 • 21 citations

Similar self-renewal properties for different sizes of human primary melanoma colonies replated in agar.

1985 • 13 citations

Differential lysis of melanoma clones by autologous recombinant interleukin 2‐activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx)

1988 • 12 citations

Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK)

1988 • 11 citations